Brentuximab vedotin for treatment of systemic T-cell lymphoma

Bibliography

• Chihara D, Ito H, Matsuda T, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol 2014;164(4):536-45
   PubMed Web of Science ®Google Scholar
• Swerdlow S, Campo E, Harris N, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer (IARC), Lyon, France; 2008
   Google Scholar
• Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26(25):4124-30
   PubMed Web of Science ®Google Scholar
• Federico M, Rudiger T, Bellei M, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol 2013;31(2):240-6
   PubMed Web of Science ®Google Scholar
• Weisenburger DD, Savage KJ, Harris NL, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011;117(12):3402-8
   PubMed Web of Science ®Google Scholar
• Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol 2013;31(16):1970-6
   PubMed Web of Science ®Google Scholar
• Sutherland MS, Sanderson RJ, Gordon KA, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 2006;281(15):10540-7
   PubMed Web of Science ®Google Scholar
• Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30(18):2190-6
   PubMed Web of Science ®Google Scholar
• Pro B, Advani RH, Brice P, et al. Three-year survival results from an ongoing phase 2 study Of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood 2013;122:abstract 1809
   Google Scholar
• Bartlett NL, Chen R, Fanale MA, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol 2014;7:24
   PubMed Web of Science ®Google Scholar
• Gibb A, Jones C, Bloor A, et al. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica 2013;98(4):611-14
   PubMed Web of Science ®Google Scholar
• Sabattini E, Pizzi M, Tabanelli V, et al. CD30 expression in peripheral T-cell lymphomas. Haematologica 2013;98(8):e81-2
   PubMed Web of Science ®Google Scholar
• Went P, Agostinelli C, Gallamini A, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 2006;24(16):2472-9
   PubMed Web of Science ®Google Scholar
• Delabie J, Holte H, Vose JM, et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood 2011;118(1):148-55
   PubMed Web of Science ®Google Scholar
• Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009;113(17):3931-7
   PubMed Web of Science ®Google Scholar
• Karube K, Aoki R, Nomura Y, et al. Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases. Pathol Int 2008;58(2):89-97
   PubMed Web of Science ®Google Scholar
• Ohtsuka E, Kikuchi H, Nasu M, et al. Clinicopathological features of adult T-cell leukemia with CD30 antigen expression. Leuk Lymphoma 1994;15(3-4):303-10
   Web of Science ®Google Scholar
• Benner MF, Jansen PM, Vermeer MH, Willemze R. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood 2012;119(7):1643-9
   PubMed Web of Science ®Google Scholar
• Edinger JT, Clark BZ, Pucevich BE, et al. CD30 expression and proliferative fraction in nontransformed mycosis fungoides. Am J Surg Pathol 2009;33(12):1860-8
   PubMed Web of Science ®Google Scholar
• Miranda RN, Aladily TN, Prince HM, et al. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol 2014;32(2):114-20
   PubMed Web of Science ®Google Scholar
• Oki Y, Younes A. Brentuximab vedotin in systemic T-cell lymphoma. Expert Opin Biol Ther 2012;12(5):623-32
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single agent brentuximab vedotin. Blood 2014;123(20):3095-100
   PubMed Web of Science ®Google Scholar
• Duvic M, Tetzlaff M, Clos AL, et al. Phase II Trial Of brentuximab vedotin for CD30+ cutaneous T-Cell lymphomas and lymphoproliferative Disorders. Blood 2013;122:abstract 367
   Web of Science ®Google Scholar
• Krathen M, Sundram U, Bashey S, et al. Brentuximab Vedotin demonstrates significant clinical activity in relapsed or refractory mycosis fungoides with variable cd30 expression. Blood 2012;120:abstract 797
   Google Scholar
• d’Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012;30(25):3093-9
   PubMed Web of Science ®Google Scholar
• Reimer P, Rudiger T, Geissinger E, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009;27(1):106-13
   PubMed Web of Science ®Google Scholar
• Schmitz N, Trumper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010;116(18):3418-25
   PubMed Web of Science ®Google Scholar
• Fanale MA, Horwitz SM, Forero-Torres A, et al. Brentuximab vedotin administered before, during, and after multi-agent chemotherapy in patients (pts) with newly-diagnosed CD30+ mature T- and NK-cell lymphomas. Blood 2013;122:abstract 4386
   Web of Science ®Google Scholar
• O’Connor OA, Pro B, Illidge T, et al. Phase III trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+ mature T-cell lymphomas (MTCL). J Clin Oncol 2013;31:abstract TPS8611
   Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 2012;30(18):2183-9
   PubMed Web of Science ®Google Scholar
• Fanale MA, Forero-Torres A, Rosenblatt JD, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res 2012;18(1):248-55
   PubMed Web of Science ®Google Scholar
• Gandhi M, Evens AM, Fenske TS, et al. Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event. Blood 2013;122:abstract 4380
   Google Scholar
• Coiffier B, Pro B, Prince HM, et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol 2014;7(1):11
   PubMed Web of Science ®Google Scholar
• Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012;30(6):631-6
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011;29(9):1182-9
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Masszi T, Savage KJ, et al. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial [abstract 8507]. ASCO annual meeting abstracts; 2013
   Google Scholar